The FDA is actively investigating Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys following two patient deaths linked to acute liver failure. The agency is evaluating potential regulatory actions as Sarepta implements enhanced safety protocols and suspends use in high-risk patients. The deaths, occurring shortly after treatment, have significantly impacted Sarepta’s stock price amid ongoing scrutiny of gene therapy safety profiles.